Endonovo Therapeutics, Inc.
OTCPK:ENDV 株式レポート
Endonovo Therapeutics マネジメント Endonovo Therapeuticsの CEO はAlan Collierで、 Mar2012年に任命され、 の在任期間は 12.67年です。 は、会社の株式の11.35%を直接所有しており、その価値は$ 47.28K 。経営陣と取締役会の平均在任期間はそれぞれ7.7年と5.4年です。
主要情報 CEO給与比率 n/a CEO在任期間 12.7yrs CEOの所有権 11.3% 経営陣の平均在職期間 7.7yrs 取締役会の平均在任期間 5.4yrs
経営陣の近況
Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical Expansion Dec 01
Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate Development Mar 03
すべての更新を表示 Endonovo Therapeutics, Inc. announced delayed 10-Q filing Nov 17
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval Oct 13 Endonovo Therapeutics, Inc. announced delayed 10-Q filing Aug 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing May 17
Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical Expansion Dec 01
Endonovo Therapeutics, Inc. announced delayed 10-Q filing Nov 15
Endonovo Therapeutics, Inc. (OTCPK:ENDV) entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star. Sep 29
Endonovo Therapeutics, Inc. announced delayed 10-Q filing Aug 16
Endonovo Therapeutics Releases Comparative Analysis Demonstrating Jul 29
Endonovo Therapeutics, Inc. announced delayed 10-Q filing May 17
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt Apr 16
Endonovo Therapeutics, Inc. announced delayed annual 10-K filing Apr 01
Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate Development Mar 03
Endonovo Therapeutics, Inc. announced delayed 10-Q filing Aug 17
Endonovo Therapeutics, Inc. announced delayed 10-Q filing May 18
Endonovo Therapeutics, Inc. announced delayed annual 10-K filing Apr 02
Endonovo Therapeutics, Inc. announced delayed 10-Q filing Nov 18
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic Oct 10
Endonovo Therapeutics, Inc. announced delayed 10-Q filing Aug 12
CEO報酬分析 Endonovo Therapeutics の収益と比較して、Alan Collier の報酬はどのように変化したか? 日付 総報酬 給与 会社業績 Sep 30 2023 n/a n/a -US$4m
Jun 30 2023 n/a n/a -US$4m
Mar 31 2023 n/a n/a -US$9m
Dec 31 2022 US$850k US$300k -US$18m
Sep 30 2022 n/a n/a -US$3m
Jun 30 2022 n/a n/a -US$4m
Mar 31 2022 n/a n/a -US$3m
Dec 31 2021 US$300k US$300k -US$3m
Sep 30 2021 n/a n/a -US$8m
Jun 30 2021 n/a n/a -US$7m
Mar 31 2021 n/a n/a -US$7m
Dec 31 2020 US$300k US$300k -US$396k
Sep 30 2020 n/a n/a -US$4m
Jun 30 2020 n/a n/a -US$4m
Mar 31 2020 n/a n/a -US$11m
Dec 31 2019 US$315k US$300k -US$17m
Sep 30 2019 n/a n/a -US$10m
Jun 30 2019 n/a n/a -US$15m
Mar 31 2019 n/a n/a -US$8m
Dec 31 2018 US$300k US$300k -US$6m
Sep 30 2018 n/a n/a -US$6m
Jun 30 2018 n/a n/a -US$7m
Mar 31 2018 n/a n/a -US$4m
Dec 31 2017 US$789k US$300k -US$11m
報酬と市場: Alanの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。
報酬と収益: Alanの報酬は増加しましたが、会社は利益を上げていません。
CEO(最高経営責任者 Mr. Alan Brian Collier has been the Chief Executive Officer at Endonovo Therapeutics, Inc. since March 2012 and serves as its Chairman and served as its Secretary since March 2012. He served as Interim Chi ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Chairman & CEO 12.7yrs US$850.00k 11.35% $ 47.3k Vice President of Operations 12.7yrs データなし データなし Head of Corporate Development 2.7yrs データなし データなし President & Chief Commercial Officer of Medical Division 2yrs データなし データなし
もっと見る
経験豊富な経営陣: ENDVの経営陣は経験豊富で 経験豊富 です(平均在職期間は7.7年)。
取締役 名称 ポジション 在職期間 報酬 所有権 Chairman & CEO 12.7yrs US$850.00k 11.35% $ 47.3k Member of Scientific Advisory Board 5.5yrs データなし データなし Member of Scientific Advisory Board 5.4yrs データなし データなし Member of Scientific Advisory Board 5.3yrs データなし データなし Member of Scientific Advisory Board 5.3yrs データなし データなし Member of Scientific Advisory Board 5.2yrs データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし
もっと見る
経験豊富なボード: ENDVの 取締役会 は 経験豊富 であると考えられます ( 5.4年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}